About Regentis Biomaterials
Regentis Biomaterials is a company based in Or Akiva (Israel) founded in 2004. It operates as a HealthTech. Regentis Biomaterials has raised $25 million across 6 funding rounds from investors including dsm-firmenich, European Union and Haisco Pharmaceutical Group. Regentis Biomaterials offers products and services including GelrinC. Regentis Biomaterials operates in a competitive market with competitors including Augmenix, AmacaThera, LifeSprout, Carbylan and Biosyntech, among others.
- Headquarter Or Akiva, Israel
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Regentis Biomaterials Ltd.
-
Annual Revenue
$51.03 K (USD)960as on Dec 31, 2018
-
Net Profit
$4.8 M (USD)0as on Dec 31, 2024
-
EBITDA
$932 K (USD)0as on Dec 31, 2024
-
Total Equity Funding
$25 M (USD)
in 6 rounds
-
Latest Funding Round
$6.5 M (USD), Post-IPO
Jun 17, 2026
-
Investors
dsm-firmenich
& 8 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Regentis Biomaterials
Regentis Biomaterials is a publicly listed company on the AMEX with ticker symbol RGNT in USA. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Regentis Biomaterials
Regentis Biomaterials offers a comprehensive portfolio of products and services, including GelrinC.
A resorbable hydrogel implant for tissue regeneration used.
Funding Insights of Regentis Biomaterials
Regentis Biomaterials has successfully raised a total of $25M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $6.5 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Regentis Biomaterials
Regentis Biomaterials has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include dsm-firmenich, European Union and Haisco Pharmaceutical Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Early-stage venture capital firm investing in Israel and US
|
Locked | Locked | Locked | |
|
A venture capital firm focused on life science investments.
|
Locked | Locked | Locked |
Investor details for Regentis Biomaterials
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Regentis Biomaterials
Investment portfolio details for Regentis Biomaterials
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Regentis Biomaterials
Detailed financials for Regentis Biomaterials
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Regentis Biomaterials Comparisons
Peer comparison for Regentis Biomaterials
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Regentis Biomaterials
Regentis Biomaterials operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Augmenix, AmacaThera, LifeSprout, Carbylan and Biosyntech, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Hydrogel spacers are provided for prostate cancer radiation therapy.
|
|
| Locked | Locked | Locked |
Injectable hydrogel platform developed for therapeutic medical applications.
|
|
| Locked | Locked | Locked |
Synthetic soft tissue substitutes for cosmetics and reconstructive surgery
|
|
| Locked | Locked | Locked |
Hyaluronic acid polymers are developed into therapeutics for pain management.
|
|
| Locked | Locked | Locked |
Biotherapeutic thermogels are developed for tissue repair applications.
|
Detailed competitors of Regentis Biomaterials
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Regentis Biomaterials
Complete news archive for Regentis Biomaterials
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Regentis Biomaterials
Regentis Biomaterials was founded in 2004 and raised its 1st funding round 8 years after it was founded.
Regentis Biomaterials is headquartered in Or Akiva, Israel. It is registered at Or Akiva, Central District, Israel.
Regentis Biomaterials is a funded company, having raised a total of $25M across 6 funding rounds to date.
Annual revenue of Regentis Biomaterials is $51.03K as on Dec 31, 2018.
Regentis Biomaterials is engaged in developing and commercializing an innovative hydrogel platform for repairing damaged tissue. The companys primary focus is on orthopedic treatments using resorbable hydrogel implants to regenerate damaged or diseased tissue. Operations are centered in the healthcare sector, specifically in biotechnology and tissue engineering solutions.
Regentis Biomaterials's top competitors include AmacaThera, Augmenix and LifeSprout.
Regentis Biomaterials offers GelrinC.
Yes, Regentis Biomaterials is publicly traded on AMEX under the ticker symbol RGNT.
Regentis Biomaterials has 9 investors. Key investors include dsm-firmenich, European Union, Haisco Pharmaceutical Group, TRDF, and EIC Fund.
The ticker symbol of Regentis Biomaterials is RGNT on AMEX.